Immune response to vaccines is maintained in patients treated with dimethyl fumarate

Conclusions:
DMF-treated patients mount an immune response to recall, neoantigens, and T-cell–independent antigens, which was comparable with that of IFN-treated patients and provided adequate seroprotection.

ClinicalTrials.gov identifier:
NCT02097849.

Classification of evidence:
This study provides Class II evidence that patients with RRMS treated with DMF respond to vaccinations comparably with IFN-treated patients.

Source: Neurology Neuroimmunology and Neuroinflammation - November 15, 2017 Category: Neurology Authors: von Hehn, C., Howard, J., Liu, S., Meka, V., Pultz, J., Mehta, D., Prada, C., Ray, S., Edwards, M. R., Sheikh, S. I. Tags: All Immunology, All Infections, Multiple sclerosis Article Source Type: research